Navigation Links
CT angiography highly accurate, multicenter trials show
Date:11/26/2007

CHICAGO Computed tomography (CT) angiography is as accurate as an invasive angiogram in detecting coronary artery disease, according to the findings of the first two prospective multicenter 64-slice scanner trials presented today at the annual meeting of the Radiological Society of North America (RSNA).

These two trials with comparable results clearly set the stage for the widespread adoption of and reimbursement for coronary artery CT examinations, said Gerald D. Dodd III, M.D., chair of the Department of Radiology at the University of Texas Health Science Center in San Antonio.

For the Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography (CORE-64) Trial, researchers at nine international centers studied 291 patients who were scheduled to undergo invasive coronary angiography for suspected or unknown coronary artery disease. The study found that 64-slice multidetector CT angiography was highly accurate in detecting blockages of greater than 50 percent, with a sensitivity of 85 percent and a specificity of 90 percent. The noninvasive exam was equal in accuracy to invasive angiography in its ability to identify patients to be referred for angioplasty or bypass surgery.

Reliable assessment of the presence of coronary blockages and accurate prediction of coronary revascularizations are feasible with 64-slice CT coronary angiography, said presenter Marc Dewey, M.D., radiologist at Humboldt University Berlin, Charit, Germany. Patients with low to intermediate risk of having coronary blockages are most likely to benefit from coronary CT angiography, since in those patients the necessity of invasive angiography is greatly reduced.

The Assessment by Coronary Computed Tomographic Angiography of Individuals UndeRgoing InvAsive Coronary AngiographY (ACCURACY) Trial compared 64-row coronary computed tomographic angiography (CCTA) to quantitative coronary angiography (QCA). The results demonstrated that CCTA is highly accurate in detecting coronary blockages in chest pain patients referred for invasive coronary angiography and is also an effective noninvasive method to exclude obstructive coronary blockages.

Sixteen institutions performed CCTA on 232 patients with typical or atypical chest pain prior to invasive coronary angiography. Findings were then compared to those of QCA, the reference standard used to quantify the results of the invasive coronary angiography.

A total of 82 blockages greater than 50 percent in 49 patients and 31 blockages greater than 70 percent were detected in 28 patients by QCA. Per-patient sensitivity and specificity of CCTA were 93 percent and 82 percent, respectively, for blockages greater than 50 percent, and 91 percent and 84 percent for blockages greater than 70 percent. In addition, negative predictive value was 97 to 99 percent.

In a population of chest pain patients with a low to intermediate prevalence of obstructive coronary artery blockages, CCTA performed highly accurately compared to invasive coronary angiography, said presenter James K. Min, M.D., assistant professor of radiology and medicine at New York Presbyterian Hospital and director of the Cardiac Computed Tomography Laboratory and Cornell University Medical Center. These findings demonstrate the high diagnostic performance of CCTA.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Catheter angiography may be an unnecessary follow-up to CT angiography
2. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
3. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
4. 18F-DG PET/CT can highly increase the detection of colorectal cancer
5. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
6. Medical University of South Carolina Leads Multicenter Study Evaluating Biliary Sphincter Disorder
7. Study Questions Dead-End Cancer Clinical Trials
8. Clinical trials present better alternatives for dialysis patients
9. IMPACT initiative looks to improve patient participation in clinical trials
10. Clinical Trials Directive still hampering academic medical research
11. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... Trinity Health today launched its inaugural ... aimed at improving care and reducing readmission rates for patients who are dually ... Health is to drive innovation that transforms our ministry and our industry to ...
(Date:5/4/2016)... SCOTTSDALE, AZ (PRWEB) , ... May 04, 2016 ... ... 2016 Annual Technology & Business Conference. The conference opened on Tuesday with Frank ... panel discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model ...
(Date:5/4/2016)... ... ... Level 10 Head Over Heels Athletic Arts’ gymnast Alessandra Brovedani -- who goes ... fall of 2019. , After a handful of college visits, the Berkeley High ... her connection with the coaching staff and the excitement surrounding Wildcat Athletics. , “What ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... therapy products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... hip replacement patients. The plush design enhances comfort and enables the patient to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , “I’m excited for our eighth summer here ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the launch ... address the nutritional needs of recovery for a variety of clinical conditions. Founded in ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)...  Deerfield announced today it led the $44.5 ... Graybug Vision is an early stage pharmaceutical company ... for ocular diseases including wet age-related macular degeneration ... developed at Johns Hopkins University and has been ... Graybug Vision is developing ophthalmology products enabling ...
Breaking Medicine Technology: